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Introduction: Variation contributing to the risk of Parkinson's disease (PD) has been identified in several
genes and at several loci including GBA, SMPD1, LRRK2, POLG1, CHCHD10 and MAPT, but the frequencies of
risk variants seem to vary according to ethnic background. Our aimwas to analyze how variation in these
genes contributes to PD in the Finnish population.
Methods: The subjects consisted of 527 Finnish patients with early-onset PD, 325 patients with late-
onset PD and 403 population controls. We screened for known genetic risk variants in GBA, SMPD1,
LRRK2, POLG1, CHCHD10 and MAPT. In addition, DNA from 225 patients with early-onset Parkinson's
disease was subjected to whole exome sequencing (WES).
Results: We detected a significant difference in the length variation of the CAG repeat in POLG1 between
patients with early-onset PD compared to controls. The p.N370S and p.L444P variants in GBA contributed
to a relative risk of 3.8 in early-onset PD and 2.5 in late-onset PD. WES revealed five variants in LRRK2 and
SMPD1 that were found in the patients but not in the Finnish ExAC sequences. These are possible risk
variants that require further confirmation. The p.G2019S variant in LRRK2, common in North African
Arabs and Ashkenazi Jews, was not detected in any of the 849 PD patients.
Conclusions: The POLG1 CAG repeat length variation and the GBA p.L444P variant are associated with PD
in the Finnish population.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Genetic variation contributing to the risk of Parkinson's disease
(PD) has been identified. One of the genes involved is gluco-
sylceramidase beta (GBA) that codes for a lysosomal enzyme. It is
traditionally associated with Gaucher's disease, but heterozygous
mutations are an established risk factor for Parkinson's disease. The
two most common mutations in GBA include p.L444P and p.N370S.tment of Neurology, P.O. Box
).SMPD1 encodes another gene involved in lysosomal function. It
codes for the protein sphingomyelin phosphodiesterase 1 that
generates ceramide by cleaving the phosphocholine group of
sphingomyelin. Mutations in SMPD1 are found in Niemann-Pick
disease and the variant p.L302P has been suggested to be associ-
ated with PD [1].
The LRRK2 (leucine-rich repeat kinase 2) gene encodes a 2527-
amino acid protein with several structural and functional domains
such as leucine-rich repeat and kinase. The common p.G2019S
mutation is located in the kinase domain and it has been shown to
increase the kinase activity [2]. The frequency of the p.G2019S
mutation varies greatly in different populations being most com-
mon in North African Arabs, where it is found in 39% of sporadic
Table 1









Controls 263 (90.1) 29 (9.9) 0 292
EOPD 452 (86.1) 68 (13.0) 5 (1.0) 525





Controls 555 (95.0) 29 (5.0) 584
EOPD 972 (92.6) 78 (7.4) 1050
LOPD 610 (94.4) 36 (5.6) 646
EOPD, early-onset Parkinson's disease; LOPD, late-onset Parkinson's disease.
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10% of sporadic and 28% of familial cases. Among Europeans, the
frequency is 4% in sporadic cases in Portugal and 14% in familial
cases, whereas in Spain, Italy and France it is 2e4%, and in Sweden
and Norway the frequency is 1%. In Asian countries the mutation is
very rare being found in <0.1% of patients [3]. The penetrance of
p.G2019S is high, but not complete, so that the risk of PD is 74% at
the age of 79 years [3].
Other genes, where variation may contribute to the risk of PD,
include POLG1, CHCHD10 and MAPT. Polymerase g (POLG1) is
responsible for the replication of the mitochondrial genome. The
second exon of the gene harbors a microsatellite consisting of ten
CAG trinucleotide repeats that is translated into a tract of ten
glutamine moieties (10Q). Genotypes different from the common
10Q variant have been associated with a higher risk of PD [4].
CHCHD10 encodes a coiled-coil helix coiled-coil helix protein that is
involved in the maintenance of mitochondrial cristae integrity [5].
The variant p.S59L in CHCHD10 has been associated with a complex
phenotype consisting of amyotrophic lateral sclerosis, fronto-
temporal lobar degeneration, cerebellar ataxia, parkinsonism, and
myopathy [5] and, subsequently, another variant p.G66V has been
identified [6]. MAPT (microtubule-associated protein tau) is
involved in the assembly and stabilization of microtubules. Of the
two haplotypes H1 and H2, haplotype H1 has been reported to be
slightly more common in PD patients than in population controls
[7].
Previous data have shown that the frequencies of these muta-
tions in patients with PD vary according to ethnic background [8].
Therefore, we screened for the most common known mutations in
the genes GBA, SMPD1, LRRK2 and CHCHD10, determined the length
variation in POLG1 and determined the MAPT haplotype in Finnish
patients with Parkinson's disease and population controls.
2. Subjects and methods
2.1. Patients and controls
The study group consisted of a national cohort of 441 patients
with EOPD defined by age of onset <55 years [9]. In addition, a case
series collected at the Kuopio University Hospital during one year
[10] comprised of 209 patients with late-onset Parkinson's disease
(LOPD) and 55 patients with EOPD, and a case series collected at the
Helsinki University Hospital [4] comprised 116 patients with LOPD
and 31 patients with EOPD. Previous analyses on these cohorts have
not revealed causative mutations in the common PD genes. Con-
trols consisted of 403 healthy blood donors from three different
regions of Finland. Part of the samples in the national cohort of
EOPD (N¼ 225) were subjected towhole exome sequencing (WES).
The study has been approved by the Ethics Committee of Turku
University Hospital, the Ethics Committee of the Medical Faculty of
the University of Kuopio, the Ethics Committee of Helsinki Uni-
versity Hospital and the Ethics committee of the Finnish Red Cross.
Written informed consent was obtained from all patients prior to
participating the study.
2.2. Molecular methods
Genomic DNA was extracted from peripheral blood using stan-
dard protocols. The variations in GBA (p.N370S, p.L444P), SMPD1
(p.L302P), LRRK2 (p.R1441C/G/H, p.G2019S), CHCHD10 (p.S59L,
p.G66V) and MAPT (haplotype H1) were detected using a PCR-
restriction digestion protocol. The primers and restriction en-
zymes used are presented in supplementary table. The detected
variations were confirmed by sequencing.
The CAG repeat in exon 2 of the POLG1 gene was analyzed byfragment length analysis. A fragment containing the CAG repeat
was amplified using a FAM-labeled forward primer CTCCGAGGA-
TAGCACTTGC and a reverse primer CTGGGTCTCCAGCTCCGT
(CHLC.GCT14A01.P16693.1 and CHLC.GCT14A01.P16693.2, respec-
tively; GenBank accession number G16014). The fragment length
was 124 bp in the presence of the most common allele containing
ten CAG repeats. The fluorescent-labeled PCR products in the EOPD
group were separated on an ABI PRISM® 3100 Genetic Analyzer
(Perkin Elmer, Foster City, CA, U.S.A.). GeneScan™ 500 LIZ® Size
Standard (Applied Biosystems, Foster City, CA, U.S.A.) was used as
an internal standard and was run along with each sample. The al-
leles were identified using the Peak Scanner™ Software Version 1.0
(Applied Biosystems). In the LOPD group and the controls an ABI
PRISM™ 377 DNA Sequencer (Perkin Elmer) was used with Gen-
escan version 2.1 fragment analysis software (Perkin Elmer). GEN-
ESCAN-500™ TAMRA (Applied Biosystems) was used as an internal
standard and the Genotyper 2.0 program (Perkin Elmer) was used
for identifying the alleles.
WES was carried out as described previously [11]. Annovar [12],
SNPEff [13] and SNPSift [14] were used for functional annotations.
The data were unfiltered so that even the unlikely SNPs could be
detected. As controls we used 563 STAMPEED population controls
from the North Finland Birth Cohort 1966. WES has recently
revealed several mutations, but no splice mutations, in established
EOPD genes among the 225 EOPD patients [11]. Clinical significance
of the mutations is, however, unknown. Nonsynonymous muta-
tions in LRRK2 and SMPD1 that were more frequent among the
patients than among the controls were verified by direct
sequencing and were analysed for their pathogenic potential by
using PredictSNP [15].2.3. Statistical analysis
Fisher exact test was used to compare allele frequencies be-
tween patients and controls. The frequency distribution of the CAG
repeat alleles in the POLG1 genewas analyzed with the exact test of
population differentiation using the Arlequin software [16].3. Results
3.1. Genetic variants contributing to the risk of EOPD
None of the EOPD patients harbored SMPD1 p.L302P, LRRK2
p.R1441C/G/H, LRRK2 p.G2019S, CHCHD10 p.S59L or CHCHD10
p.G66V. The frequency of haplotype H1 in MAPT was 92.6% in the
patients and 95.0% in the 292 controls (p ¼ 0.068 for difference,
Table 1). The length of the CAG repeat in the POLG1 gene varied
between 8Q and 13Q in the EOPD patients and between 8Q and 12Q
in the controls. The frequency distribution of the CAG repeat alleles
Table 3
Frequencies of GBA mutations in patients with PD and controls.
Mutation EOPD N (%) LOPD N (%) Controls N (%)
p.N370S 2 (0.4) 2 (0.6) 1 (0.3)
p.L444P 13 (2.5) 4 (1.2) 2 (0.5)
EOPD, early-onset Parkinson's disease; LOPD, late-onset Parkinson's disease.
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(p ¼ 0.041, exact test of population differentiation). The frequency
of non-10Q alleles was 10.7% in the EOPD patients (Table 2) and
6.8% in the controls (p ¼ 0.0056 for difference). Seven EOPD pa-
tients harbored a non-10Q/non-10Q genotype, while none of the
controls had such a genotype. The clinical features, age of PD onset
and the frequency of family history did not differ between EOPD
patients harboring a non-10Q/non-10Q genotype (n ¼ 7) and EOPD
patients with 10Q/10Q genotype (n ¼ 397). However, postural
instability and on-off variation was less common in patients with
non-10Q/non-10Q genotype.
Two EOPD patients and one control had the heterozygous
p.N370S mutation in GBA and 13 patients and two controls had the
heterozygous p.L444P mutation (p ¼ 0.032, Fisher's exact test,
Table 3). One of the patients with p.N370S also had the POLG1
variants p.N468D and p.A1105T that has been reported previously
[17]. Three of the patients with p.L444P in GBA also had the non-
synonymous p.A456P variant and the synonymous rs1135675
variant at codon 460, which in combination with p.L444P form the
RecNciI allele.
3.2. Genetic variants contributing to the risk of late-onset PD
The fivemutations in SMPD1, LRRK2 or CHCHD10were not found
in 323 LOPD patients. The frequency of haplotype H1 in MAPT was
94.4% in LOPD patients (p ¼ 0.73 for difference, Table 1). Two LOPD
patients had the heterozygous p.N370S mutation and four patients
had the heterozygous p.L444P mutation in GBA (Table 3). Inter-
estingly, one patient had both p.L444P and p.N370S mutations. The
frequency distribution of the CAG repeat alleles in the POLG1 gene
did not differ between the LOPD patients and the controls (p¼ 0.13,
exact test of population differentiation, Table 2). The frequency of
the POLG1 non-10Q alleles was 7.9% in LOPD and three LOPD pa-
tients harbored a non-10Q/non-10Q genotype.
3.3. Variation in WES in GBA, MAPT, SMPD1, LRRK2
As the well-known variants in LRRK2 and SMPD1 were notTable 2




N % N % N %
8/10 3 0.6 2 1.0 3 0.7
8/11 1 0.2 1 0.5 0
9/9 1 0.2 0 0
9/10 22 4.4 10 4.8 11 2.7
9/11 1 0.2 1 0.5 0
9/12 1 0.2 0 0
10/10 397 80.0 179 85.6 348 86.4
10/11 56 11.3 11 5.3 31 7.7
10/12 10 2.0 2 1.0 10 2.5
10/13 1 0.2 2 1.0 0
11/11 2 0.4 1 0.5 0
11/13 1 0.2 0 0
All 496 209 403
non-10/non-10 7 1.4 3 1.4 0
Allele
8 4 0.4 3 0.7 3 0.4
9 26 2.6 11 2.6 11 1.4
10 886 89.3 385 92.1 751 93.2
11 63 6.4 15 3.6 31 3.9
12 11 1.1 2 0.5 10 1.2
13 2 0.2 2 0.5 0
All 992 418 806
non-10 106 10.7 33 7.9 55 6.8
EOPD, early-onset Parkinson's disease; LOPD, late-onset Parkinson's disease.detected in the Finnish patients with EOPD, we then selected
randomly 225 out of the 441 samples to WES. Rare variation was
detected in LRRK2 and SMPD1 (Table 4), where we found five
nonsynonymous variants that were present in patients but not in
Finnish ExAC controls. Two variants were deemed to be deleterious
(Table 4) and, interestingly, the p.R542Q variant in SMPD1 was
homozygous and the p.R1628P in LRRK2 has previously been re-
ported in association with PD [18].4. Discussion
We detected a significant difference in POLG1 CAG repeat length
variation between the patients with EOPD and the controls and in
the frequency of the GBA variant p.L444P. The p.G2019S variant in
LRRK2 was not found among Finnish PD patients, although it has
previously been found in European PD patients and is especially
common among North African Arab and Ashkenazi Jewish PD pa-
tients [3]. WES revealed several variants in LRRK2 and SMPD1 that
were found only in PD patients and not in the controls. These are
putative risk variants, but require further confirmation.
The two most common mutations p.L444P and p.N370S
comprise more than 50% of the pathogenic mutations in GBA. The
allele frequency of the two mutations is high among Ashkenazi
Jewish PD patients with a total frequency of 15.3%. The combined
frequency of the two mutations is approximately 3.2% in non-
Ashkenazi Jewish PD patients [8], 2.3% in Norwegian patients [8]
and 2.8% in Swedish patients [19], whereas among non-Finnish
Europeans in the ExAC database the frequency is 0.8%. We found
these GBA mutations in 2.8% of the EOPD patients giving a relative
risk of 3.8 for PD and in 1.9% of the LOPD patients giving a relative
risk of 2.5. Patients with a GBA mutation appear to have an earlier
onset of PD compared to that in patients without mutations [8]. In
Finnish EOPD patients with a GBA mutation the mean age of onset
was 44.6 years and at least five out of the 15 mutation carriers
reported PD in a first-degree relative.
The variants p.G2019S in LRRK2 and p.L302P in SMPD1 are
associated with increased risk of PD [1,20]. We did not find these
variants in our samples, but WES revealed five other variants that
were not found in the controls. PredictSNP suggested that the
LRRK2 variant p.R1628P is deleterious. This variant has been
previously associated with PD in Chinese and Thai populations
[18]. The p.R1628P variant acts by turning its adjacent amino acid
residue S1627 to a new phosphorylation site of Cdk5. Cdk5
phosphorylation of p.S1627 in the presence of p.R1628P increases
the LRRK2 kinase activity. Interestingly, cultured mouse cortical
neurons transfected with p.R1628P LRRK2 plasmids show a
higher sensitivity of to MPPþ [21]. Our two patients with
p.R1628P had an age of onset of 44 and 49 years and had no
family history of PD.
The homozygous SMPD1 p.L302P mutation causes a fatal in-
fantile type A Niemann-Pick disease. This mutation in heterozygous
state has previously been shown to be associated with Parkinson's
disease [1]. We did not find p.L302P among Finnish PD patients, but
WES revealed two other variants that were not found in controls.
PredictSNP suggested that the SMPD1 variant p.R542Q was dele-
terious, while p.E358K was neutral. The frequency of p.R542Q is
Table 4
Rare variants in exome sequences of LRRK2 and SMPD1.
Gene Position Ref Alt dbSNP Amino acid change PredictSNP Patients with variant (n) Finnish alleles in ExAC
(n)
Effect Accuracy (%) All With variant
Variants not present in controls
SMPD1 6413367 G A n.a. p.E358K N 63 1 6558 0
SMPD1 6415566 G A rs113467489 p.R542Q D 65 1 6614 0
LRRK2 40693018 G T n.a. p.C1152F N 75 1 n.d. n.d.
LRRK2 40713842 C T rs201637880 p.S1627L N 83 1 n.d. n.d.
LRRK2 40713845 G C rs33949390 p.R1628P D 72 2 6610 0
Ref, reference variant; Alt, alternative variant; dbSNP, reference SNP ID; n.a., not available; N, neutral; D, deleterious; n.d., not detected; ExAC, Exome Aggregation Consortium.
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and, interestingly, the patient was homozygous. Clinically the pa-
tient with p.R542Q was unremarkable with an age of onset of 54
years and with no family history of PD. Homozygous p.R608del
mutation has been described previously in a patient with PD and
type B Niemann-Pick disease [22].
The length of the CAG repeat in POLG1 varies between 5 and 16
trinucleotides [23,24]. We detected a difference in the repeat allele
distribution between EOPD patients and controls and a difference
in the frequency of non-10Q alleles. A difference in the frequency of
non-10/11Q alleles has previously been obtained in Finnish [4],
Swedish [23], Norwegian [24] and Chinese populations [25], but
not among North American Caucasians [26]. The latter study,
however, reported a higher frequency of non-10Q alleles among PD
patients, whereas no difference has been found in this frequency
between Australian PD patients and controls [27]. These associa-
tions suggest that polymerase g protein harboring the non-10Q
stretch contributes directly to the risk of PD or that the non-10
CAG repeat alleles represent markers of harmful variants else-
where in the gene. The protein harboring a non-10Q polyglutamine
tract could be less optimal in protein-protein interactions [28].
Furthermore, estimation of mRNA folding energies in silico has
shown that the folding energy is lower in the shorter POLG variants
and higher in the longer variants [23].
We found that there are common alleles in the Finnish popu-
lation that increase the risk of PD. The POLG1 non-10Q variants
were associated with an increased risk of PD and the GBA p.L444P
variant contributed to a relative risk of 4.9 with respect to EOPD.
Interestingly, we did not detect the p.G2019S variant in LRRK2 that
is common in other populations, butWES revealed other variants in
this gene and in SMPD1 that were found only in PD patients sug-
gesting that they are putative risk variants.Author contributions
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